Seroatlas · Human Serome Atlas

GPN2

GPN-loop GTPase 2

Also known as: ATPBD1B, FLJ10349, GPN2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9H9Y4
Gene: GPN2
Ensembl: ENSG00000142751
Chromosome: 1
Canonical length: 310 aa
Protein class: Predicted intracellular proteins

OverviewNCBI Gene

Predicted to enable GTPase activity. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

310 residues, UniProt reviewed canonical sequence.

>Q9H9Y4|GPN2
     1  MAGAAPTTAF GQAVIGPPGS GKTTYCLGMS EFLRALGRRV AVVNLDPANE GLPYECAVDV
    61  GELVGLGDVM DALRLGPNGG LLYCMEYLEA NLDWLRAKLD PLRGHYFLFD CPGQVELCTH
   121  HGALRSIFSQ MAQWDLRLTA VHLVDSHYCT DPAKFISVLC TSLATMLHVE LPHINLLSKM
   181  DLIEHYGKLA FNLDYYTEVL DLSYLLDHLA SDPFFRHYRQ LNEKLVQLIE DYSLVSFIPL
   241  NIQDKESIQR VLQAVDKANG YCFRAQEQRS LEAMMSAAMG ADFHFSSTLG IQEKYLAPSN
   301  QSVEQEAMQL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against GPN2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.28
Highest tissue expression: 21 nTPM

Expression across tissuesHPA

Tissue

skeletal muscle: 21 nTPM
adrenal gland: 21 nTPM
bone marrow: 20 nTPM
esophagus: 20 nTPM
tonsil: 19 nTPM
liver: 19 nTPM

Single-cell type

syncytiotrophoblasts: 60 nCPM
oocytes: 55 nCPM
tuft cells: 46 nCPM
cytotrophoblasts: 46 nCPM
migrating cytotrophoblasts: 43 nCPM
esophageal suprabasal cells: 40 nCPM

Immune cell

non-classical monocyte: 35 nTPM
intermediate monocyte: 34 nTPM
eosinophil: 32 nTPM
naive B-cell: 31 nTPM
memory B-cell: 30 nTPM
T-reg: 30 nTPM

Brain region

cerebellum: 25 nTPM
medulla oblongata: 24 nTPM
white matter: 23 nTPM
cerebral cortex: 23 nTPM
hypothalamus: 23 nTPM
basal ganglia: 22 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about GPN2.

Disease | GeneticClinVar

1 pathogenic / likely-pathogenic of 63 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Perrault syndrome 1

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.85
gnomAD pLI: 0.01
gnomAD missense Z: 0.17
DepMap mean gene effect: -1.83
DepMap dependency class: pan

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Molecular functions

Protein domainsUniProt · Pfam · InterPro

GPN-loop GTPase
P-loop containing nucleoside triphosphate hydrolase
Conserved hypothetical ATP binding protein
GPN-loop GTPase 2

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of GPN2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads GPN2 as an antibody target. Whether an autoantibody or antibody against GPN2 could matter depends on whether native GPN2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

GPN2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label GPN2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...